Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. - Wikidata - awgldk - TriplyDB

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

http://www.wikidata.org/entity/Q37372822

about

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer Melanoma: oncogenic drivers and the immune system Strategies for combining immunotherapy with radiation for anticancer therapy Ly49 receptors: innate and adaptive immune paradigms Natural killer cell biology: an update and future directions Immunotherapy in the treatment of non-small cell lung cancer Killer immunoglobulin-like receptors and tumor immunity Current perspectives on natural killer cell education and tolerance: emerging roles for inhibitory receptors The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Emerging role of Natural killer cells in oncolytic virotherapy Targeted immunotherapy for acute myeloid leukemia Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor Features of Memory-Like and PD-1(+) Human NK Cell Subsets Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies Advances in Cancer Immunotherapy in Solid Tumors Immune checkpoint blockade: a common denominator approach to cancer therapy Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer Understanding of molecular mechanisms in natural killer cell therapy Innate or adaptive immunity? The example of natural killer cells Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade NK cell-based immunotherapy for malignant diseases.Biology and clinical effects of natural killer cells in allogeneic transplantation.Nivolumab in NSCLC: latest evidence and clinical potential Natural killer cell-based therapies.NK cells, innate immunity and hepatitis C infection after liver transplantation.Cytokines reinstate NK cell-mediated cancer immunosurveillance.Cytokine therapy reverses NK cell anergy in MHC-deficient tumors Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.Antibody-based therapies in multiple myeloma Natural killer cell engineering for cellular therapy of cancer NK cells: immune cross-talk and therapeutic implications.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women.

P2860

Q26738359-678B4106-0045-4DA3-99D5-FF4526BFEF93 Q26747397-02BAF1F5-A5AF-42BB-8360-A4955FBDD30D Q26751011-1D31FECB-4BE7-4BCF-9D15-50695F386279 Q26752518-66C8684E-4CE3-48B0-B422-97EEAFA59E0A Q26765459-DF39C762-C037-4757-8290-BBC9BCD8D484 Q26765845-5FEE1221-D737-436D-A56E-569EE0CA2BAE Q26774678-D13AB949-EC4A-4FF6-8D33-1B14C32BBA9D Q26775598-7F9CB4E2-2FBB-4EC7-A9DE-75BB5EC0B51E Q26796675-8C33D0D0-F0A9-4A07-A4FF-3EC91E670F91 Q26825078-A2001B5C-E2DB-4B23-929C-5075D834C7F1 Q26830512-2132C7CF-F668-40A1-A0D3-84ADBC031503 Q27000382-6342D01F-49EE-4B96-95F5-82F0BC9AAF10 Q27005792-AE8A0247-45E8-48C7-8F9A-6760EDE8FA4C Q27009135-F07636A6-2E1F-4C35-83FF-8511EF9E71B9 Q27022789-F03FEFAB-9F80-4CA6-B5E5-E5D0220589BF Q27025330-0E8290F0-2383-4FE4-B12C-330BA0437C69 Q27687636-09D1FF3C-6D7A-4230-AAE3-7E16F3F27A02 Q28067468-91F0CEBD-4E25-4A39-8DB3-94B089D9C7B0 Q28073988-99472C78-DCE0-4C94-9473-CE4E503D8F60 Q28079180-A3015F1D-0018-4980-A81B-52C0DA24DDAF Q28080113-D45712BC-18A9-4EBC-980F-9785CD29819C Q28083981-628E7234-5C27-4F47-8230-AA86DD0D5119 Q28084766-8F29D440-2AF5-4ED7-BD70-D18B37D86E1C Q28086976-6A6EDDD9-05A7-4CF2-B167-B7E6ABEAEBD5 Q29615106-F8F944D4-DC84-4079-933D-D4DECFBBA714 Q33672480-2A2D3CF8-794E-4EED-95F3-FF75219F02C9 Q33787859-13C997EA-F00E-4BA9-86E8-D03EF5FDDE88 Q33827433-B0B049A3-7826-4626-84E5-57668BC5AE70 Q33893173-2A0DFB84-EB45-457C-9699-6675BCA15553 Q34466452-B74A8795-58D8-485B-A4CD-73BFDFE73DBC Q34988727-4B7782FA-69D5-4B50-A061-81C49CBCA24A Q35019869-7562B71C-694B-43C2-9683-083AB1D0460E Q35140082-F5D9518E-9133-45D8-B154-A2DEBA92A5CE Q35140125-FFC948CE-E391-46B0-AD57-508E1AB6C5D2 Q35208414-EED18C01-73E8-4E81-A086-5A6B1C94A015 Q35431150-0286963B-3B32-4C87-AFB7-5430F577AAF9 Q35556865-BD55D4D1-88B9-4097-B86D-833BFDCC44C9 Q35591444-6E6BB548-5293-49DE-BED5-73B4EFE2B9DC Q35600095-BEEA9246-A260-4554-8CC8-6352382930EE Q35904239-2D7DE2D0-DB0C-40CC-A939-BEB98749FE4B

P2860

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

http://www.wikidata.org/entity/Q37372822

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preclinical characterization o ...... diated killing of tumor cells.

@en

Preclinical characterization o ...... diated killing of tumor cells.

@nl

type

label

Preclinical characterization o ...... diated killing of tumor cells.

@en

Preclinical characterization o ...... diated killing of tumor cells.

@nl

prefLabel

Preclinical characterization o ...... diated killing of tumor cells.

@en

Preclinical characterization o ...... diated killing of tumor cells.

@nl

P1433

Q37372822-56B98A8F-BCE5-4A9B-BE1D-98E88E0BEB47

P1476

Q37372822-1A3AF79D-30E0-45E0-B3B5-CDE6664E60AC

P2093

Q37372822-0BBC6899-F99F-42FD-86B8-EF9C36B61CEC

Q37372822-1B0C3FD5-C598-4725-89E8-59E510087FDD

Q37372822-1FE3B8E6-B3EF-489C-9A67-C0E0358563F6

Q37372822-32E52E1F-0F20-4321-841D-5C36AB0D61F8

Q37372822-57D5B868-0716-40A7-BB53-12B505BCF2A7

Q37372822-768F8C2C-AB63-4443-BFD0-F6F4E077F811

Q37372822-7D09E91F-8159-4AB9-9EFF-6530DD2FBACB

Q37372822-81B1E88E-7058-4A7D-B82C-B81E232E59BA

Q37372822-950923B5-7BC1-4F3E-BBC4-4A8CDE4D9701

Q37372822-994DF1F3-0A8D-494C-B6EA-20C3C18C845B

P2860

Q37372822-013984D7-0199-4830-9D14-1D1EB8E1F30F

Q37372822-04E6AF5D-A1B2-4F77-9D84-5C5A04B247FA

Q37372822-06FF7E4E-2D4E-45FA-B466-B55EE0EA8CD3

Q37372822-07B53D1D-10A9-4E6F-89F8-7E9DF6945563

Q37372822-1091FDB4-6502-4ACA-9B2C-4DB8CCCD5BBD

Q37372822-10EDBF51-005A-4963-B19B-B54CFB34D746

Q37372822-160D3920-F52D-4862-B8F8-4EE14BCAD52F

Q37372822-1670B916-228F-40E2-8E6E-E363B59E8058

Q37372822-181069E4-6A6E-4F77-AB8B-79492D28F742

Q37372822-21D25ACC-DA34-4ACD-856C-557EDB97276B

P304

Q37372822-28B936B5-A03B-47A4-854D-E6312D7B03C4

P31

Q37372822-5E969E63-5025-40A3-A16B-F219985940FD

P356

Q37372822-7320D062-8093-486F-9E3E-44DF1C965598

P407

Q37372822-7E022DDB-3921-49E1-B093-BF7DE088EADD

P433

Q37372822-697AA9FC-2A7D-4FD5-BCAE-F4F8CC77344B

P478

Q37372822-EC441807-3B5F-4769-84B9-E94E68D734B0

P50

Q37372822-4467BD1C-A4E3-4B6B-AC9D-FACD232FBEA8

Q37372822-AD45E43F-5D32-4A5C-8918-2F1061AFD3D8

P577

Q37372822-FBF713A0-AFCC-4DCC-A4EF-3156B9C85D4E

P5875

Q37372822-4388E09F-3EB0-4B48-9D74-D627749F8B2D

P698

Q37372822-F0D9B0AB-E1DE-480C-AF3A-281943919201

P921

Q37372822-9DFBBCB2-5318-4D4A-88A7-3BC184FF8143

P932

Q37372822-E109D3F1-F869-4355-9F29-7D0C2574C3B4

P356

BLOOD-2009-02-206532

P1433

P1476

Preclinical characterization o ...... diated killing of tumor cells.

@en

P2093

Alessandro Moretta

http://www.w3.org/2001/XMLSchema#string

Andrea Velardi

http://www.w3.org/2001/XMLSchema#string

Don M Benson

http://www.w3.org/2001/XMLSchema#string

Francois Romagné

http://www.w3.org/2001/XMLSchema#string

Laurent Gauthier

http://www.w3.org/2001/XMLSchema#string

Loredana Ruggeri

http://www.w3.org/2001/XMLSchema#string

Mariella Della Chiesa

http://www.w3.org/2001/XMLSchema#string

Marusca Capanni

http://www.w3.org/2001/XMLSchema#string

Michael A Caligiuri

http://www.w3.org/2001/XMLSchema#string

Nicolai Wagtmann

http://www.w3.org/2001/XMLSchema#string

P2860

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions

A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation

Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains

Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells

Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay

The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells

Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors

Functions of natural killer cells

NK cell recognition

P304

2667-2677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-02-206532

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Bradley W Blaser

P577

2009-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26318026

http://www.w3.org/2001/XMLSchema#string

P698

19553639

http://www.w3.org/2001/XMLSchema#string

P921

P932

2756126

http://www.w3.org/2001/XMLSchema#string